|
|
Overview
Understanding your industry
Highly regulated and closely monitored, the industry is characterised by:
-
complex regulatory frameworks;
-
lengthy premarket development periods and licensing regimes;
-
the importance of the development, ownership and protection of technology; and
-
high levels of investment.
Our team understands the drivers for participants in this industry sector.
We have lawyers who are experienced in all phases of the industry from assisting “start-up” and smaller companies in research and development, capital raisings and the commercialisation and protection of intellectual property through to assisting well-established multinationals with compliance with Therapeutic Goods and Trade Practices legislation and protection of their intellectual property. Our experience in the resolution of tender and contracting issues with government at all levels, the financing of large scale operations, and experience in the acquisition and disposal of businesses in this sector enhance our ability to add value to industry participants.
How we can help
Our services include:
-
commercial advice
-
regulatory and administrative advice including TGA and TPA
-
trade mark registration and portfolio management
-
enforcement of patent, trade mark, design, copyright and confidential information rights
-
product recalls and product liability
-
compliance programs and risk management
-
medical malpractice and disciplinary
-
product development and innovation
-
marketing, packaging and comparative advertising advice
-
government tendering and probity advice
-
trade Practices advice and compliance programs
-
medical products and services insurance
-
advice on veterinary laws
|
|
Best Lawyers Australia 2009
Group member Andrew Saxton has been judged by his peers to be one of Australia's 6 top lawyers in the category of Medical Negligence and one of Australia's 17 top lawyers in the category of Health and Aged Care... more |
|
Article: Journal of Law & Medicine - Using mediation in situations of withholding or withdrawing life - sustaining treatment: A New South Wales perspective
|
|
Article: Sigma ordered not to release its generic antidepressant
On 3 June 2009, Justice Sundberg granted an interlocutory injunction in the latest patent stoush between a pharmaceutical innovator and a generic pharmaceutical company. The decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth continues the recent trend towards granting interlocutory injunctions in pharmaceutical patent cases... more |
|
Article: Interlocutory Injunctions in Pharmaceutical Patent Cases
Applications for interlocutory injunctions before Australian courts are generally governed by the three well established legal principles. Arguably, in the case of a pharmaceutical patent... more |
|
Article: Is there any role for health care professionals at the mediation of clinical negligence claims?
|
|
